AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8536905
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg glucagon (Study 1)
Trial: 8536905
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg glucagon (Study 2)
Trial: 8536905
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg glucagon (both studies)
Trial: 2302870
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) administration of recombinant human erythropoietin (rHuEPO) at 50 U/kg body weight
Trial: 2302870
Drug: Intraperitoneal (i.p.)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (i.p.) administration of recombinant human erythropoietin (rHuEPO) at 50 U/kg body weight
Trial: 580863
Drug: guanadrel sulfate
RxNorm normalized name: guanadrel sulfate
DrugBank: Guanadrel (DB00226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: guanadrel sulfate (5 to 20 mg orally every six hours)
Trial: 21762151
Drug: 0.1%w/w o‐cymen‐5‐ol/
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1%w/w o‐cymen‐5‐ol/ 0.6%w/w zinc chloride gel to foam dentifrice
Trial: 19282350
Drug: Panitumumab in
RxNorm normalized name: panitumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab in combination with bevacizumab and chemotherapy
Trial: 19282350
Drug: Bevacizumab and
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab and chemotherapy alone
Trial: 9106580
Drug: Baclofen 10
RxNorm normalized name: baclofen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 10 mg three times daily
Trial: 3472436
Drug: Home blood
RxNorm normalized name: LifeSource Aneroid Home Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home blood pressure (Home-BP) measured three times daily during a two week period
Trial: 30393062
Drug: Antiplatelet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet treatment (users at baseline)
Trial: 30393062
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (users at baseline)
Trial: 10895736
Drug: Fluconazole 100
RxNorm normalized name: fluconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 100 mg tablets once per day
Trial: 10895736
Drug: Clotrimazole 10
RxNorm normalized name: clotrimazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 10 mg troches five times per day
Trial: 3899840
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin (total 200 mg) and chloroquine (total 1.5 g)
Trial: 3538324
Drug: SLO4 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLO4 oral drops
Trial: 31475507
Drug: Anterior QLB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior QLB + intravenous PCA morphine (Group B)
Trial: 31475507
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA morphine (Group C)
Trial: 28426917
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral therapy (iCBT) program for depression added to treatment as usual (TAU)
Trial: 26021225
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (no other antibiotic administration)
Trial: 26021225
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (1 g of amoxicillin in the evening of the day of surgery and 1 g twice a day for 2 days after)
Trial: 18803892
Drug: Intravenous 5
RxNorm normalized name: immune globulin intravenous 5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5 IU oxytocin + 0.5 mg ergometrine
Trial: 16580284
Drug: Oral analgesia
RxNorm normalized name: P-A-C Analgesic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesia with oxycodone‐acetaminophen
Trial: 16580284
Drug: Morphine patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine patient‐controlled analgesia device
Trial: 1357554
Drug: Salmeterol (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (42 micrograms twice daily)
Trial: 1357554
Drug: Albuterol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (180 micrograms four times daily)
Trial: 3914251
Drug: Conventional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional steroid and azathioprine therapy
Trial: 25882919
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice capsules (2 capsules, 2 times a day for 6 weeks)
Trial: 25882919
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo, 2 capsules, 2 times a day for 6 weeks)
Trial: 21301848
Drug: Liposomal cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal cisplatin 200 mg/m2 combined with paclitaxel 135 mg/m2
Trial: 21301848
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 combined with paclitaxel 135 mg/m2
Trial: 19625240
Drug: Alendronate therapy
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate therapy (10 mg daily)
Trial: 11684630
Drug: Carvedilol (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (nonselective beta-blocker)
Trial: 7814117
Drug: Minimal cavity
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal cavity preparation and composite resin only
Trial: 2773832
Drug: Dietary cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cholesterol (equal to about two egg yolks daily)
Trial: 19437505
Drug: Internet‐based cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet‐based cognitive‐behavioral treatment with minimal contact via e‐mail
Trial: 8186348
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg long-acting (LA)
Trial: 3283917
Drug: Novaluzid, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novaluzid, 10 ml four times daily
Trial: 23900048
Drug: Dicholoroacetate and
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicholoroacetate and 2 tyrosine kinase inhibitors (imatinib and sunitinib)
Trial: 14737728
Drug: 0.5‐1cm deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐1cm deep marker injection
Trial: 14737728
Drug: Sub‐epithelial marker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub‐epithelial marker injection
Trial: 10632651
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg, Amoxycillin 1 g, and Clarithromycin 500 mg (OAC) b.d. for 1 week
Trial: 10632651
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (Bismuth subcitrate 120 mg, Tetracycline 500 mg, Metronidazole 400 mg q.d.s. plus Omeprazole 20 mg b.d.)
Trial: 8959612
Drug: Focused stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused stimulation intervention administered by parents
Trial: 8959612
Drug: Delayed-treatment (control)
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-treatment (control) group
Trial: 7934140
Drug: Cisplatin treatment
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin treatment in vitro
Trial: 3287592
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at a rate of 2 mU/kg/min with concomitant glucose infusion to maintain euglycaemia
Trial: 3287592
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion with falling blood glucose (no glucose infusion)
Trial: 12595281
Drug: Diuretic (Hypo;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (Hypo; 100 mg/day spironolactone for 3 days)
Trial: 10992369
Drug: Former PSA
RxNorm normalized name: Triple Wormer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Former PSA testing or digital rectal examination
Trial: 2360466
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) as prophylactic treatment
Trial: 2360466
Drug: No long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No long-term AEDs treatment in patients without preoperative epilepsy
Trial: 17597050
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg once daily
Trial: 15114776
Drug: Postoperative intravesicular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative intravesicular immunotherapy with ronkoleucine 1,000,000 IU
Trial: 15114776
Drug: Postoperative intravesicular
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative intravesicular immunotherapy with ronkoleucine 500,000 IU
Trial: 11407666
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary angioplasty + Helicobacter pylori eradication therapy
Trial: 11407666
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary angioplasty + placebo treatment
Trial: 12707127
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine 2 mg/kg
Trial: 968923
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (17‐ethinyl 1,3,5‐estratriene 3,17 diol)
Trial: 968923
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (90 mg estradiol valerianate and 300 mg 17‐hydroxy‐19‐norprogesterone caproate)
Trial: 21851167
Drug: Taprenepag isopropyl
RxNorm normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taprenepag isopropyl (0.005%, 0.01%, 0.015%) in unfixed combination with latanoprost 0.005%
Trial: 9051282
Drug: Psychological therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapies for generalized anxiety disorder
Trial: 29743087
Drug: α‐lipoic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐lipoic acid (0.3 g/d)
Trial: 29743087
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (1.3 g/d)
Trial: 29743087
Drug: EPA+α‐LA (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+α‐LA (1.3 g/d + 0.3 g/d)
Trial: 17151341
Drug: Optimized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized medical treatment (n = 10)
Trial: 11590509
Drug: HAART therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART therapy (including indinavir or ritonavir or hard-gel saquinavir-containing regimens)
Trial: 9781603
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg twice daily by mouth
Trial: 9781603
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CF at 20 mg/m2 IV push, 5-FU at 325 mg/m2 IV daily for 5 days/week, and interferon alpha-2A 5 x 10(6) units/m2 SC on days 1, 3, 5
Trial: 7886777
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg aminosidine base/kg/d for 7 d
Trial: 7886777
Drug: 12 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg/d for 14 d
Trial: 7886777
Drug: 18 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg/kg/d for 14 d
Trial: 2963059
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol combined with ipratropium bromide
Trial: 6344899
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol alone
Trial: 6965579
Drug: Propranolol, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 10 mg orally every 6 hours
Trial: 15379146
Drug: LAC250 (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC250 (lansoprazole 30 mg, amoxicillin 1000 mg, clarithromycin 250 mg)
Trial: 15379146
Drug: LAC500 (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC500 (lansoprazole 30 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Trial: 11451214
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (2.5-80 mg)
Trial: 11451214
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (20 mg and above)
Trial: 8066909
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose of budesonide via Nebuhaler
Trial: 8066909
Drug: Half normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half normal dose of budesonide via Turbuhaler
Trial: 3058131
Drug: Salbutamol dry
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol dry powder inhaled from Salbutamol cyclocaps Pharbita 0.4 mg
Trial: 31048638
Drug: Combined Ahmed
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Ahmed Glaucoma Valve (AGV) implantation and trabeculectomy revision with adjunctive antimetabolite
Trial: 31048638
Drug: Combined AGV
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined AGV implantation and trabeculectomy revision with adjunctive antimetabolite
Trial: 27908840
Drug: Taper support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper support intervention (psychiatric consultation, opioid dose tapering, and 18 weekly meetings with a physician assistant)
Trial: 27908840
Drug: Taper support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper support intervention
Trial: 26065500
Drug: 200mg oral
RxNorm normalized name: AVANAFIL 200MG ORAL TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg oral ketoconazole twice a day plus 5% natamycin (Group B)
Trial: 16983674
Drug: Double-pass, low-energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-pass, low-energy treatment (8-11 J/cm²)
Trial: 16983674
Drug: Single-pass, high-energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-pass, high-energy treatment (13-14 J/cm²)
Trial: 11519636
Drug: Methylphenidate (15-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (15-90 mg)
Trial: 11519636
Drug: Triazolam (0.125-0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125-0.75 mg)
Trial: 9762776
Drug: Specific IgA
RxNorm normalized name: Food specific IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgA antibodies to Dermatophagoides farinae
Trial: 9762776
Drug: Specific IgA
RxNorm normalized name: Food specific IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgA antibodies to Streptococcus pneumoniae
Trial: 9762776
Drug: Specific IgG
RxNorm normalized name: Mold specific IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgG antibodies to Dermatophagoides farinae
Trial: 9762776
Drug: Specific IgG
RxNorm normalized name: Mold specific IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgG antibodies to Streptococcus pneumoniae
Trial: 3354494
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of fructose
Trial: 3354494
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g of glucose
Trial: 30056030
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg risankizumab every 4 weeks for 12 weeks (open-label intravenous therapy)
Trial: 30056030
Drug: Open-label subcutaneous
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label subcutaneous risankizumab (180 mg) every 8 weeks for 26 weeks (maintenance phase)
Trial: 30056030
Drug: Open-label intravenous
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label intravenous risankizumab (600 mg)
Trial: 30056030
Drug: Open-label subcutaneous
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label subcutaneous risankizumab (180 mg)
Trial: 24126646
Drug: MARS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MARS with conventional treatment (n = 53)
Trial: 24126646
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n = 49)
Trial: 18451376
Drug: Fluoride treatment
RxNorm normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoride treatment (1.23 percent sodium fluoride)
Trial: 17198066
Drug: 4-L polyethylene
RxNorm normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-L polyethylene glycol (PEG) solution
Trial: 12975595
Drug: Quinapril (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (titrated to 40 mg/day) for 6 months
Trial: 1587378
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day conjugated estrogens cyclically (CE; 25 days/month)
Trial: 1587378
Drug: 0.625 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/day conjugated estrogens continuously
Trial: 1587378
Drug: 50 micrograms/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms/day of transdermal 17 beta‐estradiol cyclically (24 days/month)
Trial: 3983885
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol 1.25 mg
Trial: 3983885
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol 2.5 mg
Trial: 3983885
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol 5 mg
Trial: 3983885
Drug: Control (oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oxygen and corticosteroid treatment withheld)
Trial: 16033247
Drug: 3% cork
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% cork extract gel
Trial: 12445027
Drug: Co-artemether with
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Co-artemether with ketoconazole (400 mg on day 1 followed by 200 mg o.d. for 4 additional days)
Trial: 1743751
Drug: Lincomycin 300
RxNorm normalized name: lincomycin 300 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lincomycin 300 mg intramuscularly daily in a single dose
Trial: 6852325
Drug: Amcinonide preparations
RxNorm normalized name: Amcinonide
DrugBank: Amcinonide (DB00288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amcinonide preparations and Betnovate cream applied once daily
Trial: 6852325
Drug: Amcinonide preparations
RxNorm normalized name: Amcinonide
DrugBank: Amcinonide (DB00288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amcinonide preparations and Betnovate cream applied twice daily
Trial: 6852325
Drug: Amcinonide preparations
RxNorm normalized name: Amcinonide
DrugBank: Amcinonide (DB00288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amcinonide preparations and Betnovate cream applied every alternate day
Trial: 6852325
Drug: Amcinonide preparations
RxNorm normalized name: Amcinonide
DrugBank: Amcinonide (DB00288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amcinonide preparations and Betnovate cream with an initial three times daily loading dose on the first day
Trial: 22512509
Drug: 12 NB‐UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 NB‐UVB exposures over 4 weeks (mean cumulative dose 48·4 standard erythema doses)
Trial: 22512509
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg of oral cholecalciferol daily for 4 weeks